Eurythmy Therapy (ERYT) as a Treatment Option for Fatigue in Metastatic Breast Cancer Patients

Breast Cancer Clinical Trial

— ERYT  

Official title:

Eurythmy Therapy (ERYT) as a Treatment Option for Fatigue in Metastatic Breast Cancer Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04024267
• Other study ID #: 123123
• Status: Recruiting
• Phase: N/A
• Start date: March 10, 2020
• Est. completion date: November 30, 2024

Study information

• Verified date: July 2023
• Source: University of Bern
• Contact: Ursula Wolf, Professor
• Phone: +41 (0)31 684 81 40
• Email: ursula.wolf[@]unibe.ch
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cancer related fatigue (CRF) is the most burdening symptom in breast cancer patients, and prevalence exceeds 75% in patients with metastatic disease. CRF is described as the symptom that has the largest impact on quality of life, with negative effects on work, social activities, and daily activities, and may lead to treatment discontinuation. Currently, there is no gold standard for the treatment of CRF. Drug therapies are not satisfactory. Since physical activity is associated with significant reduction in CRF, patients are encouraged to engage in an at least moderate level of physical activity. However, for many metastatic breast cancer patients this is too burdensome. Finally, there is some evidence that non-pharmacological mind-body techniques may be beneficial in reducing CRF, yet the available data do not allow for final recommendations. Given the high prevalence of CRF and the substantial distress for patients, advancing treatment options for patients with CRF is highly desirable. In the present study, patients with metastatic breast cancer will be randomly assigned to two different non-pharmacological treatments for fatigue: Eurythmy therapy (ERYT), a standardized active mindful movement therapy, or a movement program without mindfulness features (CoordiFit). It will be tested, if ERYT has a superior benefit on fatigue compared to CoordiFit over the period of the intervention (20 weeks). Further, the benefit of ERYT on quality of life, sleep quality, anxiety, depression, pain, mobility of the arm, rate of return to work, compliance with ERYT, and targeted metabolomics will be investigated. Both groups will have equal frequency and duration of the training sessions. Each patient will receive 13 standardized therapy sessions of 45 min (once a week for 6 weeks and once every second week) during the total period of 20 weeks. The proposed study has been developed in the Breast Cancer Project Group of the Swiss Group for Clinical Cancer Research (SAKK) and is supported by many breast centers, because they realize that the patients value non-pharmacological treatment options and would be keen to participate in such a trial. If ERYT proves to be beneficial, the impact of this trial will be high and will have implications not only for metastatic breast cancer patients but also for other cancer patients, health care personnel, scientists and funding and regulatory bodies.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 196
• Est. completion date: November 30, 2024
• Est. primary completion date: November 30, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Female, aged 18 years or older
• Histologically or cytologically confirmed metastatic breast cancer
• FACIT-F subscale score < 34 (considered as cut-off for a diagnosis of relevant fatigue; a score < 30 is considered as severe fatigue [83])
• Eastern Cooperative Oncology Group (ECOG) grade 1 or 2
• Ability to physically and cognitively perform an active movement therapy
• Ability to provide informed consent as documented by signature
• Ability to read, write, and speak German, French, or Italian

Exclusion Criteria:

• Inability or contraindication that would prevent prolonged follow-up, or to undergo the investigated intervention or control intervention, in the opinion of the investigator
• Patients with psychiatric, addictive or any disorder that prevents the patient from adhering to the protocol requirements, in the opinion of the investigator
• Significant uncontrolled cardiac disease (e.g. unstable angina, recent myocardial infarction)
• Haemoglobin < 90 g/L

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Fatigue

Intervention

Other:
• Eurythmy therapy
Mind-body therapy
• CoordiFit
Fitness training

Locations

Country	Name	City	State
Switzerland	Brustzentrum Basel Bethesda Spital	Basel
Switzerland	St. Clara Forschung AG	Basel
Switzerland	Engeriedspital	Bern
Switzerland	Hirslanden Bern AG, Salem-Spital, Brustzentrum Bern Biel	Bern
Switzerland	Institute of Complementary and Integrative Medicine, University of Bern	Bern
Switzerland	University Hospital Bern	Bern
Switzerland	Tumorzentrum ZeTuP Rapperswil-Jona	Rapperswil-Jona
Switzerland	Brustzentrum Ostschweiz AG	Saint Gallen
Switzerland	Kantonsspital St.Gallen, Zentrum für Integrative Medizin	Saint Gallen
Switzerland	Tumor- und Brustzentrum ZeTuP AG	Saint Gallen
Switzerland	Kantonsspital Winterthur, Medizinische Onkologie und Hämatologie	Winterthur

Sponsors (2)

Lead Sponsor	Collaborator
University of Bern	Breast Cancer Research Foundation

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in fatigue over the whole intervention	Fatigue is measured using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F). FACIT-F consists of the Functional Assessment of Cancer Therapy - General (FACT-G) plus the fatigue subscale comprising 13 fatigue-related items, with a total of 41 items. The fatigue subscale score is ranging from 8 to 44. A score < 34 is considered as cut-off for a diagnosis of relevant fatigue.	End of the intervention (week 20)
Secondary	Change from baseline in quality of life over the whole intervention	Quality of life is measured using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F). FACIT-F consists of the Functional Assessment of Cancer Therapy - General (FACT-G) plus the fatigue subscale comprising 13 fatigue-related items, with a total of 41 items. The FACT-G subscale score ranges from 0 to 108. The higher the FACT-G subscale score the better the quality of life.	End of the intervention (week 20)
Secondary	Change from baseline in patient's distress over the whole intervention	Patient's distress is measured using the National Comprehensive Cancer Network (NCCN) Distress thermometer. The NCCN Distress thermometer ranges from 0 to 10, with 10 indicating an extreme distress and 0 indicating no distress.	End of the intervention (week 20)
Secondary	Change from baseline in sleep quality over the whole intervention	Sleep quality is measured using the Pittsburgh Sleep Quality Index (PSQI). The PSQI total score of the 9 items ranges from 0 to 21. A score < or = 5 is associated with good sleep quality; a score > 5 is associated with poor sleep quality.	End of the intervention (week 20)
Secondary	Change from baseline in pain over the whole intervention	Pain is measured using the Brief Pain Inventory (BPI). The BPI assesses pain at its "worst", "least", "average", and "now" (current pain). The four severity items range from 0 ("no pain") to 10 ("pain as bad as you can imagine").	End of the intervention (week 20)
Secondary	Change from baseline in depression over the whole intervention	Depression is assessed using the Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 total score for the nine items ranges from 0 to 27. Scores of 5, 10, 15, and 20 represent cutpoints for mild, moderate, moderately severe, and severe depression, respectively.	End of the intervention (week 20)
Secondary	Change from baseline in anxiety over the whole intervention	Anxiety disorders are assessed using the General Anxiety Disorder-7 (GAD-7). The GAD-7 total score for the seven items ranges from 0 to 21. Scores of 5, 10, and 15 represent cutpoints for mild, moderate, and severe anxiety, respectively.	End of the intervention (week 20)